These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 17005666)

  • 1. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
    Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
    J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.
    Palmer KE; Benko A; Doucette SA; Cameron TI; Foster T; Hanley KM; McCormick AA; McCulloch M; Pogue GP; Smith ML; Christensen ND
    Vaccine; 2006 Jun; 24(26):5516-25. PubMed ID: 16725236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children.
    Marais DJ; Sampson CC; Urban MI; Sitas F; Wiliamson AL
    J Med Virol; 2007 Sep; 79(9):1370-4. PubMed ID: 17607783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
    Breitburd F; Kirnbauer R; Hubbert NL; Nonnenmacher B; Trin-Dinh-Desmarquet C; Orth G; Schiller JT; Lowy DR
    J Virol; 1995 Jun; 69(6):3959-63. PubMed ID: 7745754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic DNA immunization against multiple papillomavirus types.
    Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
    Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge.
    Govan VA; Christensen ND; Berkower C; Jacobs WR; Williamson AL
    Vaccine; 2006 Mar; 24(12):2087-93. PubMed ID: 16343704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation.
    Jansen KU; Rosolowsky M; Schultz LD; Markus HZ; Cook JC; Donnelly JJ; Martinez D; Ellis RW; Shaw AR
    Vaccine; 1995 Nov; 13(16):1509-14. PubMed ID: 8578834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against papillomavirus with a polynucleotide vaccine.
    Donnelly JJ; Martinez D; Jansen KU; Ellis RW; Montgomery DL; Liu MA
    J Infect Dis; 1996 Feb; 173(2):314-20. PubMed ID: 8568291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
    Xu YF; Zhang YQ; Xu XM; Song GX
    Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
    Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papillomavirus virus-like particles as anticancer vaccines.
    Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
    Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillomavirus-like particles and HPV vaccine development.
    Schiller JT; Lowy DR
    Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
    Da Silva DM; Pastrana DV; Schiller JT; Kast WM
    Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.